|会社名||Genomic Health Inc （ゲノミック・ヘルス）|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 Guardant Health Inc. is a United States-based company that engages in non-invasive cancer genomic sequencing. The Company is focused on developing diagnostic technologies that can transform cancer from a silent killer into a manageable disease. The Company engages in next-generation sequencing single-cell genomics and cancer diagnostics. The Company offers Guardant360 which is a biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options. The 73-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases and interrogates all four types of genomic alterations. The test prevents repeat invasive biopsies when cancer has progressed or recurred despite treatment or when an initial biopsy is unobtainable or has insufficient tissue. It is the circulating tumor DNA (ctDNA) test that includes all somatic genomic targets in a single test. ゲノミック・ヘルスは米国でがんの個別化治療のためのゲノム解析(遺伝子検査)を行う。侵潤性乳がん、結腸がん、前立腺がん用の腫瘍の大きさ、悪性度、再発性、化学療法の効果性などの情報を提供するオンコタイプDX検査を行う。また、他のがんに対するオンコタイプDX検査の臨床研究を行う。 Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.|
|本社所在地||301 Penobscot Drive Redwood City CA 94063 USA|
|代表者氏名||AmirAli Talasaz アミアリタラサス|
|代表者役職名||President Chief Operating Officer Director|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Guardant Health Inc revenues increased 93% to $36.1M. Net loss applicable to common stockholders decreased 13% to $35.5M. Revenues reflect United States segment increase of 77% to $29.5M International segment increase from $2.1M to $6.6M. Lower net loss reflects G/L on early Exting of lease relat debt decrease from $5.1M (expense) to $0K Interest Exp-Net of Capitalized Interest decrease of 69% to $648K (expense).|
Bull of the Day: Guardant Health (GH) 2019/12/09 10:27:00 Zacks Investment Research
Bull of the Day: Guardant Health (GH)
Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? 2019/12/03 16:30:19 Zacks Investment Research
Is (GH) Outperforming Other Medical Stocks This Year?
How SoftBank’s Masayoshi Son became poorer by $6 bn 2019/11/06 03:20:35 The Economic Times India
By Pavel Alpeyev, Venus Feng and Takahiko HyugaMasayoshi Son is paying the price for bold bets on startups from WeWork to Uber Technologies Inc.The founder of Japan’s SoftBank Group Corp. has seen his net worth slide about $6 billion from its peak this year after his strategy of aggressively backing technology pioneers backfired. His fortune tumbled to roughly $13.8 billion as of Tuesday, according to the Bloomberg Billionaires Index, after peaking in July at about $20 billion.Son will give details of the damage on Wednesday when his Japanese conglomerate reports earnings, including likely writedowns for Uber and WeWork. The Vision Fund, its primary investment vehicle for startups, is said to be planning to swallow a charge of at least $5 billion. Some of that stems from the spectacular implosion of WeWork, the once-celebrated co-working company that SoftBank is now bailing out after systemic governance failures tanked its IPO attempt. The U.S. company, which raised money at a $47 billion valuation in January, was said to be valued at less than $8 billion in the rescue package.“Son has been through a number of ups and downs before, but it seems like these days he’s taking on more and more risk,” said Mitsushige Akino, an executive officer with Ichiyoshi Asset Management Co. in Tokyo. “What’s really spooking investors is that they don’t know if WeWork is just the tip of the iceberg for SoftBank’s trouble.”Uber and WeWork, once among the brightest stars in the SoftBank constellation, now number among its worst performers.
Double Your Money (or More!) With This Ridiculously Cheap Dividend Payer 2019/11/04 12:39:07 The Motley Fool Canada
Gamehost (TSX:GH) shares could easily double if a few important things start going right.
Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know 2019/10/30 21:50:11 Zacks Investment Research
In the latest trading session, Guardant Health (GH) closed at $70.96, marking a +0.45% move from the previous day.
Guardant health prices stock offering at $71 2019-05-23
Guardant Health ( GH ) has priced its public offering of 4.5M common shares at $71/share, for gross proceeds of $319.5M. More news on: Guardant Health, Inc., Healthcare stocks news, Read more …
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 ゲノミック・ヘルス GH Guardant Health Inc.）